Applied Genetic Technologies Co (AGTC) 20.02 $AGTC
AGTC and 4D Molecular Therapeutics Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
GlobeNewswire - Mon Apr 20, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC) and 4D Molecular Therapeutics (4DMT), leaders in next-generation adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need. As part of the agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors. Financial details were not disclosed.
AGTC: 20.02 (-1.41)
BUYINS.NET: AGTC SqueezeTrigger Price is $20.08. There is $12,849,624 That Short Sellers Still Need To Cover.
M2 - Tue Mar 31, 4:23AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring AMERICAN GILSONITE C (NASDAQ:AGTC) in real time and just received an alert that AGTC is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 626200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $20.08. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
AGTC: 20.02 (-1.41)
AGTC Appoints Bruce A. Peacock to Its Board of Directors
GlobeNewswire - Fri Mar 20, 3:05PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has appointed Bruce A. Peacock to the company's Board of Directors.
AGTC: 20.02 (-1.41)
American Gilsonite to Announce 4th Quarter and Full Year 2014 Financial Results
PR Newswire - Tue Mar 10, 9:30AM CDT
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC"
, the world's major supplier of Gilsonite®, announced that it will post financial and operating results for the fourth quarter and full year ended December 31, 2014 to the Company's Intralinks investor site on Friday, March 13, 2015.
AGTC: 20.02 (-1.41)
AGTC Files Investigational New Drug Application for the Treatment of X-Linked Retinoschisis
GlobeNewswire - Tue Mar 10, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of X-linked retinoschisis (XLRS). Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues that have been specifically engineered for better penetration to the back of the eye.
AGTC: 20.02 (-1.41)
Applied Genetic Tech CBO bids adieu
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 9:45AM CDT
AGTC: 20.02 (-1.41)
InsiderInsights.com Daily Round Up 2/24/15: TRUE, NS, D, HOS
InsiderInsights - at Seeking Alpha - Wed Feb 25, 9:17AM CST
72.52 (+0.43), TIME: 22.64 (+0.07), STFC: 23.83 (-0.01), ANET: 66.27 (+0.40), VR: 42.62 (+0.27), XRM: 18.58 (+0.19), MCHP: 49.30 (+0.08), NS: 65.49 (+1.78), USCR: 35.73 (-0.28), GOOG: 539.36 (+5.39), IBTX: 38.80 (+0.34), MAS: 26.85 (+0.50), HOS: 20.11 (-0.89), AGTC: 20.02 (-1.41), QSR: 39.36 (+0.67), CUDA: 45.71 (-0.08), TRUE: 15.72 (-0.26), PPG: 226.40 (-0.65), CAP: 24.54 (-0.22)
What's New in the Pharma Sector: New Research on Amgen, Applied Genetic Technologies, Aptose, ARIAD, and Atara Biotherapeutics
PR Newswire - Fri Feb 13, 6:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
AGTC: 20.02 (-1.41), APTO: 5.94 (-0.53), AMGN: 169.10 (+0.64), ATRA: 63.79 (+7.64), ARIA: 9.23 (-0.04)
AGTC Announces Financial Results for the Second Quarter Ended December 31, 2014
GlobeNewswire - Wed Feb 11, 9:55AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the second quarter ended December 31, 2014.
AGTC: 20.02 (-1.41)
Applied Genetic Technologies beats by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 7:28AM CST
AGTC: 20.02 (-1.41)
Applied Genetic Technologies posts 2Q loss
Automated Insights - Wed Feb 11, 7:12AM CST
ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Wednesday reported a loss of $4.7 million in its fiscal second quarter.
AGTC: 20.02 (-1.41)
AGTC Appoints Stephen W. Potter Chief Business Officer
GlobeNewswire - Thu Jan 29, 6:00AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the appointment of Stephen W. Potter as its Vice President and Chief Business Officer. In that role he will be responsible for corporate development for the company, including the commercialization of existing product candidates, exploring new opportunities for clinical stage assets, and business development initiatives. Mr. Potter, who has more than 15 years of experience as a senior executive in the biotechnology industry, succeeds Daniel L. Menichella, who resigned from his position at AGTC to pursue another opportunity.
AGTC: 20.02 (-1.41)
American Gilsonite to Provide Update on 2015 Outlook
PR Newswire - Fri Jan 23, 12:29PM CST
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC" , the world's major supplier of Gilsonite®, announced that it will host a conference call for holders of its Senior Secured Notes and other members of the financial community on Tuesday, February 10, 2015 at 10:00am ET. The purpose of this conference call will be to provide an update on the Company's 2015 outlook, and will not include detailed discussion of fourth quarter 2014 results.
AGTC: 20.02 (-1.41)
AGTC to Present at Phacilitate Cell & Gene Therapy Forum 2015
GlobeNewswire - Thu Jan 22, 6:09AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will participate in the Phacilitate Cell & Gene Therapy Forum 2015. On Tuesday, January 27, 2015 in Washington, D.C., AGTC executives will take part in the following sessions:
AGTC: 20.02 (-1.41), SIAL: 138.92 (+0.17)
Applied Genetic Technologies (AGTC) in Focus: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 8:18AM CST
Applied Genetic Technologies Corporation (AGTC) was a big mover last session, as the company saw its shares rise around 7% on the day.
AGTC: 20.02 (-1.41), ALXN: 188.19 (+1.41)
Wedbush Securities' David Nierengarten On Genetic Cures For Disease: Impossible Dream Come True?
Life Sciences Report - at Seeking Alpha - Thu Dec 11, 1:57PM CST
Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report , David Nierengarten of...
BLUE: 136.49 (+1.22), AGTC: 20.02 (-1.41), NPSP: 45.97 (+0.01)
AGTC CEO to Present at Piper Jaffray Healthcare Conference on December 3, 2014
GlobeNewswire - Tue Nov 25, 6:00AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO, will present at the 26 Annual Piper Jaffray Healthcare Conference on December 3, 2014 at 3:30pm ET in New York. Ms. Washer will provide a corporate overview discussing the company's lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). To access a live webcast of this presentation, please visit http://ir.agtc.com/. A replay will be available for two weeks following the presentation.
AGTC: 20.02 (-1.41)
Applied Genetic EPS of -$0.34
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:00PM CST
AGTC: 20.02 (-1.41)
AGTC Announces Financial Results for the First Quarter Ended September 30, 2014
GlobeNewswire - Wed Nov 12, 3:02PM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the first quarter ended September 30, 2014.
AGTC: 20.02 (-1.41)
AGTC to Present at Upcoming Conferences
GlobeNewswire - Mon Nov 10, 6:07AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced that company management will be presenting at upcoming scientific and investor conferences.
AGTC: 20.02 (-1.41)
AGTC and 4D Molecular Therapeutics Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
GlobeNewswire - Mon Apr 20, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC) and 4D Molecular Therapeutics (4DMT), leaders in next-generation adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need. As part of the agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors. Financial details were not disclosed.
AGTC: 20.02 (-1.41)
BUYINS.NET: AGTC SqueezeTrigger Price is $20.08. There is $12,849,624 That Short Sellers Still Need To Cover.
M2 - Tue Mar 31, 4:23AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring AMERICAN GILSONITE C (NASDAQ:AGTC) in real time and just received an alert that AGTC is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 626200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $20.08. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
AGTC: 20.02 (-1.41)
AGTC Appoints Bruce A. Peacock to Its Board of Directors
GlobeNewswire - Fri Mar 20, 3:05PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has appointed Bruce A. Peacock to the company's Board of Directors.
AGTC: 20.02 (-1.41)
American Gilsonite to Announce 4th Quarter and Full Year 2014 Financial Results
PR Newswire - Tue Mar 10, 9:30AM CDT
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC"
, the world's major supplier of Gilsonite®, announced that it will post financial and operating results for the fourth quarter and full year ended December 31, 2014 to the Company's Intralinks investor site on Friday, March 13, 2015. AGTC: 20.02 (-1.41)
AGTC Files Investigational New Drug Application for the Treatment of X-Linked Retinoschisis
GlobeNewswire - Tue Mar 10, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of X-linked retinoschisis (XLRS). Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues that have been specifically engineered for better penetration to the back of the eye.
AGTC: 20.02 (-1.41)
Applied Genetic Tech CBO bids adieu
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 9:45AM CDT
AGTC: 20.02 (-1.41)
InsiderInsights.com Daily Round Up 2/24/15: TRUE, NS, D, HOS
InsiderInsights - at Seeking Alpha - Wed Feb 25, 9:17AM CST
72.52 (+0.43), TIME: 22.64 (+0.07), STFC: 23.83 (-0.01), ANET: 66.27 (+0.40), VR: 42.62 (+0.27), XRM: 18.58 (+0.19), MCHP: 49.30 (+0.08), NS: 65.49 (+1.78), USCR: 35.73 (-0.28), GOOG: 539.36 (+5.39), IBTX: 38.80 (+0.34), MAS: 26.85 (+0.50), HOS: 20.11 (-0.89), AGTC: 20.02 (-1.41), QSR: 39.36 (+0.67), CUDA: 45.71 (-0.08), TRUE: 15.72 (-0.26), PPG: 226.40 (-0.65), CAP: 24.54 (-0.22) What's New in the Pharma Sector: New Research on Amgen, Applied Genetic Technologies, Aptose, ARIAD, and Atara Biotherapeutics
PR Newswire - Fri Feb 13, 6:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
AGTC: 20.02 (-1.41), APTO: 5.94 (-0.53), AMGN: 169.10 (+0.64), ATRA: 63.79 (+7.64), ARIA: 9.23 (-0.04)
AGTC Announces Financial Results for the Second Quarter Ended December 31, 2014
GlobeNewswire - Wed Feb 11, 9:55AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the second quarter ended December 31, 2014.
AGTC: 20.02 (-1.41)
Applied Genetic Technologies beats by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 7:28AM CST
AGTC: 20.02 (-1.41)
Applied Genetic Technologies posts 2Q loss
Automated Insights - Wed Feb 11, 7:12AM CST
ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Wednesday reported a loss of $4.7 million in its fiscal second quarter.
AGTC: 20.02 (-1.41)
AGTC Appoints Stephen W. Potter Chief Business Officer
GlobeNewswire - Thu Jan 29, 6:00AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the appointment of Stephen W. Potter as its Vice President and Chief Business Officer. In that role he will be responsible for corporate development for the company, including the commercialization of existing product candidates, exploring new opportunities for clinical stage assets, and business development initiatives. Mr. Potter, who has more than 15 years of experience as a senior executive in the biotechnology industry, succeeds Daniel L. Menichella, who resigned from his position at AGTC to pursue another opportunity.
AGTC: 20.02 (-1.41)
American Gilsonite to Provide Update on 2015 Outlook
PR Newswire - Fri Jan 23, 12:29PM CST
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC"
, the world's major supplier of Gilsonite®, announced that it will host a conference call for holders of its Senior Secured Notes and other members of the financial community on Tuesday, February 10, 2015 at 10:00am ET. The purpose of this conference call will be to provide an update on the Company's 2015 outlook, and will not include detailed discussion of fourth quarter 2014 results. AGTC: 20.02 (-1.41)
AGTC to Present at Phacilitate Cell & Gene Therapy Forum 2015
GlobeNewswire - Thu Jan 22, 6:09AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will participate in the Phacilitate Cell & Gene Therapy Forum 2015. On Tuesday, January 27, 2015 in Washington, D.C., AGTC executives will take part in the following sessions:
AGTC: 20.02 (-1.41), SIAL: 138.92 (+0.17)
Applied Genetic Technologies (AGTC) in Focus: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 8:18AM CST
Applied Genetic Technologies Corporation (AGTC) was a big mover last session, as the company saw its shares rise around 7% on the day.
AGTC: 20.02 (-1.41), ALXN: 188.19 (+1.41)
Wedbush Securities' David Nierengarten On Genetic Cures For Disease: Impossible Dream Come True?
Life Sciences Report - at Seeking Alpha - Thu Dec 11, 1:57PM CST
Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report , David Nierengarten of...
BLUE: 136.49 (+1.22), AGTC: 20.02 (-1.41), NPSP: 45.97 (+0.01)
AGTC CEO to Present at Piper Jaffray Healthcare Conference on December 3, 2014
GlobeNewswire - Tue Nov 25, 6:00AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO, will present at the 26 Annual Piper Jaffray Healthcare Conference on December 3, 2014 at 3:30pm ET in New York. Ms. Washer will provide a corporate overview discussing the company's lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). To access a live webcast of this presentation, please visit http://ir.agtc.com/. A replay will be available for two weeks following the presentation.
AGTC: 20.02 (-1.41)
Applied Genetic EPS of -$0.34
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:00PM CST
AGTC: 20.02 (-1.41)
AGTC Announces Financial Results for the First Quarter Ended September 30, 2014
GlobeNewswire - Wed Nov 12, 3:02PM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the first quarter ended September 30, 2014.
AGTC: 20.02 (-1.41)
AGTC to Present at Upcoming Conferences
GlobeNewswire - Mon Nov 10, 6:07AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced that company management will be presenting at upcoming scientific and investor conferences.
AGTC: 20.02 (-1.41)
